South Africa’s health regulator has approved Johnson & Johnson COVID-19 vaccines in its charge against the disease.
J&J vaccines have been undergoing test trials in eight countries of the world including South Africa where it was administered on front line health workers.
The vaccine showed 66% prevention capabilities and 85% at correcting symptoms observed.
South Africa expects 31m doses of the single-dose vaccine of the Pharmaceutical company while it also expects 20m doses from Pfizer.
The continent’s most affected country also expects some doses from the COVAX and Gavi vaccine facilities in partnership with the African Union.
South African private-owned companies have also showed interest in lifting some financial burden off the neck of the government.
With more than one million cases recorded, South Africa is the worst-hit in Africa, after a very virulent strain of the virus was found in the country.
Pfizer vaccine has shown potency against the most transmissible strains of the virus.